Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Activist investor Starboard Value has taken a stake in Becton Dickinson and is pushing the $72bn medical technology company to sell its life sciences division, according to people familiar with the ...

Pfizer shows profit growth from cost cuts and ... negotiations Healthcare & Pharmaceuticalscategory· January 17, 2025 Starboard Value has built a 7.7% stake in Qorvo , the chipmaker revealed ...

Bourla has been fighting off criticism of the leadership and strategy of Pfizer by hedge fund Starboard Value, which claims that at least $20 billion in the company's value has been drained away ...

FREE TO READ] Critics say fragmented ownership, weak culture and a fixation on financial results have harmed innovation ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...